Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per

Similar documents
APPENDIX American Diabetes Association. Published online at

To test your basal rates it will be important that you keep the same schedule on the days you are testing. Do not do basal rate testing if you:

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate

Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI

BEST 4 Diabetes. Optimisation of insulin module

January 7, 5:00 p.m. EST

Type 2 Diabetes Mellitus Insulin Therapy 2012

Adjusting Insulin Doses

Guide to Starting and Adjusting Insulin for Type 2 Diabetes*

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

BEST 4 Diabetes. Optimisation of insulin module

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Self-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Poll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.

LET S TALK INSULIN THE BASICS

Analyzing Glucose Data

Starting and Helping People with Type 2 Diabetes on Insulin

Position Statement of ADA / EASD 2012

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Module 5. Understanding Insulin Therapy

Scoring: WEll-being and Satisfaction of CAREgivers of Children with Diabetes Questionnaire (WE-CARE)

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Insulin Initiation, titration & Insulin switch in the Primary Care-KISS

Insulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology

DEMYSTIFYING INSULIN THERAPY

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

These results are supplied for informational purposes only.

Mixed Insulins Pick Me

Investigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD

Case Study: Competitive exercise

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Fine-tuning of The Dose of Insulin Pump

SHINE Study PowerChart Order Set CONTROL

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

Learning Objectives. Perioperative SWEET Success

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Diabetes Medical Management Plan

CANDY Camp Application

Welcome Everyone. Monitoring, Sick Days, Inpatient Management - Objectives. Mrs. Jones has new diabetes. She asks you: Page 1

Pharmacy Plan Guidance

Initiation and Adjustment of Insulin Regimens for Type 2 Diabetes

Comprehensive Diabetes Treatment

LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

BRIAN MOSES, MD, FRCPC (INTERNAL MEDICINE) CHIEF OF MEDICINE, SOUTH WEST HEALTH

Inpatient Glycemic Management:

INSULIN 101: When, How and What

Important Stuff. Basal Bolus What Adjustments? Pt weighs 80kg

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

SCHOOL HEALTH PLAN: DIABETES

Application of the Diabetes Algorithm to a Patient

For patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH

Glycemic Control IU Health Diabetes Centers

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

APPENDIX #1: SAMPLE Diabetes Medical Management Plan (DMMP)

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)

Injecting Insulin into Out Patient Practice

OneTouch Reveal web app Report Reference Guide

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Prior to making any insulin adjustments the following knowledge and skills are required:

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

This certificate-level program is non-sponsored.

PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES

Report Reference Guide

MANAGEMENT OF DIABETES IN PREGNANCY

Supplemental Health Record and Authorization for Care of Child with Insulin Dependent Diabetes

Your Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine

Initiating Injectable Therapy in Type 2 Diabetes

Parent Form DIABETES MEDICAL MANAGEMENT PLAN This form must be renewed each school year or with any change in treatment plan

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

4/16/2018. Flexible Intensive Insulin Therapy (FIIT) in People with Type 2 Diabetes: A Viable Option. Disclosures. Outline. No financial disclosures

Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires

Diabetes Medical Management Plan

Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk

In-hospital management of diabetes

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

Pump Mechanics and Management. Basic procedures for initiating pump therapy

New Hires Program Canadian Diabetes Educator Certification Board Competencies Addressed

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

Insulin Intensification: A Patient-Centered Approach

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT

9-A. Diabetes Medical Management Plan

Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018

Background: Brief review of epidemiology, diagnosis, classification and pathophysiology of diabetes mellistus.

2. The charges will be sent to the insurance company on one bill, but will list each date that you come to a class.

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Current Clinical Practice Guideline for Diabetes Management

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Instructions for Completing the Daily Carbohydrate/Insulin Record Form

Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

UKPDS: Over Time, Need for Exogenous Insulin Increases

Sample Exam Questions

Transcription:

APPENDIX 1 Insulin Titration Algorithm Subjects are requested to perform self-monitoring of blood glucose (SMBG) 4 times per day. All subjects will be contacted weekly to review hypoglycemia and adverse events and to discuss insulin dose adjustment. Insulin glargine dose will be adjusted on a weekly basis by the clinic staff according to the following schedule: Mean Fasting SMBG (mg/dl) Insulin Glargine Adjustment 180 Increase by 8 units 140-179 Increase by 6 units 120-139 Increase by 4 units 95-119 Increase by 2 units 70 94 No change < 70 Decrease by 10% The 3 most recent fasting SMBG values will be used to determine the mean for the week. If during the week a subject has 2 or more fasting blood glucose values < 70 mg/dl, then the dose of insulin glargine will be decreased by 10% even if subject has a mean FBG 95 mg/dl. Insulin glulisine dose will be adjusted according to the following schedule:

Pre-Meal Dose of Insulin Glulisine Pattern of Low Preprandial or Bedtime BG Values Pattern of High Preprandial or Bedtime BG Values 10 units Decrease by 1 unit Increase by 1 unit 11-20 units Decrease by 2 units Increase by 2 units > 20 units Decrease by 3 units Increase by 3 units A pattern of low BG values is defined as 2 or more preprandial or bedtime values < 70 mg/dl in a specific time period per week. A pattern of high BG is defined as 4 or more preprandial values 100 mg/dl, or 4 or more bedtime values 130 mg/dl, in a specific time period per week. The adjustment of the insulin glulisine dose is applied to the meal prior to the time period during which the pattern of high or low glucose is observed (e.g., if the pre-lunch glucose exhibits a high pattern, then the pre-breakfast dose of glulisine would be increased). If both patterns (high and low) are observed for the same time period during the week, the dose of glulisine should be decreased unless the investigator decides otherwise based on the circumstances surrounding the observed patterns. If a meal is skipped, bolus insulin planned for that meal should not be taken. Subjects will be instructed not to skip meals. Premix insulin (Humalog Mix 75/25 or Novolog Mix 70/30) will be adjusted according to the following schedule: Mean Fasting SMBG (mg/dl) Premix Adjustment Evening Dose > 180 Increase by 8 units 140-179 Increase by 6 units

120 139 Increase by 4 units 95 119 Increase by 2 units 70 94 No change < 70 Decrease by 10% Mean Pre-Dinner SMBG (mg/dl) Premix Adjustment Morning Dose > 180 Increase by 8 units 140-179 Increase by 6 units 120 139 Increase by 4 units 100 119 Increase by 2 units 70 99 No change < 70 Decrease by 10% If during the week a subject has 2 or more BG values < 70 mg/dl in a specific time period, the dose of premix insulin corresponding to that time period will be decreased. Missing Blood Glucose Values: If a subject records fewer than the recommended 28 blood glucose readings each week then titration recommendations will be made whenever possible. If the investigator judges that too few values were collected and no recommendation should be made, none will be provided. In this case the investigator will counsel the subject on the importance of glucose measurements.

APPENDIX 2 Description of Patient-Reported Outcomes Scales The 71-item Diabetes Treatment Satisfaction module assesses satisfaction with diabetes treatment of any type and includes 13 scales as listed below (number of items in parentheses): Advocacy -- recommending treatment to persons with diabetes including family and friends (2) Burden associated with adherence, diet, exercise, performing daily and social activities and enjoying life (14) Convenience remember taking medication, amount of time required to manage diabetes, required procedures (6) Perceived Efficacy patient s perception of the treatment s effectiveness to control blood sugar (3) Flexibility scheduling and allowing variability in meals and activities (4) General Satisfaction -- pleased with current medication (4) Hassle bother associated with dosing, treatment supplies, carrying supplies, supply disposal, pain and discomfort, worries about hypoglycemia and hyperglycemia (8) Interference with daily routine, meals, recreation, family life, sleep schedules, energy levels, making plans, traveling (11) Pain discomfort (3) Preference desire to search out other regimens, continue on current regimen (2) Side Effects gaining weight, unpleasant feelings, distress with hypoglycemia (5) Social interference with social interactions with family and friends, travel, recreation, work and social roles (9) Overall Satisfaction mean of the 12 treatment satisfaction scales

The 12-item Comparative Treatment Preference module provides a direct comparison of preference for either basal-bolus or premix, and covers ease, convenience, flexibility, efficacy, social functioning, and preference. Quality-of-life assessment of psychological, physical and social functioning was evaluated by the following scales (number of items in parentheses): Perceived Health (Global Analogue Scale) overall, physical, emotional, personal life and job or work (5) Functional Health Status functional levels of activities of daily living ranging from strenuous activity to basic activities such as dressing, bathing and eating (12) Diabetes-Specific Interference and General Symptom Interference each assessing interference with work, social events, recreational activities, exercise and physical activities, work effectiveness, enjoying life and feeling your best (7 each) Symptoms and Side-Effects Distress diabetes-specific and general symptoms (prevalence, frequency and distress severity) (53) Mental and Emotional Health subscales of anxiety, depression, and loss of behavioral and emotional control (Domain of Psychological Distress) and life satisfaction, positive well being, and emotional ties (Domain of Psychological Well Being) (24) General Health Perceptions sleep disturbance, vitality and general health status (11) Cognitive Function and Performance cognitive acuity, memory, reasoning, disorientation and detachment and self-rated cognitive performance (21) Sexual Symptom Distress (male and female versions) sexual interest and satisfaction, problems with sexual functioning (5 each) Psychosocial (Itemwise) -- unweighted summative score of the 11 items of General Health Perceptions and 24 items of Mental and Emotional Health

Psychosocial (Composite) -- unweighted summative score of the 9 subscales of Mental and Emotional Health and General Health Perceptions (depression, general positive affect, emotional ties, anxiety, loss of behavioral and emotional control, life satisfaction, vitality, health status, and sleep disturbance) Overall Quality of Life Factor Score factor analysis combining the scales of General Health Perceptions, Mental and Emotional Health (Psychological Distress and Psychological Well Being), Perceived Health, Symptom Distress, Cognitive Function and Performance